Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Corrigendum to “HEART UK consensus statement on Lipoprotein(a): A call to action” [Atherosclerosis 291 (2019) 62–70]

Lookup NU author(s): Dr R Neely

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2019 The Author(s)It has been brought to our attention that the wording of the German reimbursement criteria for apheresis is not clear in the above paper (Section 7. Management of patients with raised Lipoprotein(a), Subheading: Apheresis). This should read: “In Germany, Lp(a) levels exceeding 60 mg/dl and LDL-cholesterol in normal range along with progressive CVD has been approved as an indication for regular lipoprotein apheresis since 2008.”

Publication metadata

Author(s): Cegla J, Neely RDG, France M, Ferns G, Byrne CD, Halcox J, Datta D, Capps N, Shoulders C, Qureshi N, Rees A, Main L, Cramb R, Viljoen A, Payne J, Soran H

Publication type: Note

Publication status: Published

Journal: Atherosclerosis

Year: 2020

Volume: 296

Pages: 48-48

Print publication date: 01/03/2020

Online publication date: 01/02/2020

Acceptance date: 02/04/2016

ISSN (print): 0021-9150

ISSN (electronic): 1879-1484

Publisher: Elsevier Ireland Ltd

URL: https://doi.org/10.1016/j.atherosclerosis.2020.01.019

DOI: 10.1016/j.atherosclerosis.2020.01.019

Share